Dynamic Prognostic Stratification of Resectable Pancreatic Cancer Using the Metro-Pancreas Framework Post-Neoadjuvant Chemotherapy

Highlights

  • Metro-Pancreas combines tumor size and CA 19-9 to stratify prognosis in resectable pancreatic ductal adenocarcinoma (PDAC).
  • After neoadjuvant chemotherapy (NAT), Metro-Pancreas restaging improves prognostic discrimination and enables dynamic risk reassessment.
  • Reclassification from Metro-Pancreas OUT to IN post-NAT is associated with significantly improved postoperative disease-free and overall survival.
  • Integration of Metro-Pancreas with other prognostic indicators may optimize personalized treatment planning in resectable PDAC.

Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply